INTEGRATED FILING — Other than Banks



General information about company

Scrip code 000000
NSE Symbol AATMAJ
MSEI Symbol NOTLISTED
ISIN INE0OB201016
Name of Company AATMAJ HEALTHCARE LIMITED
Type of company SME
Class of security Equity
Date of start of financial year 01-04-2025
Date of end of financial year 31-03-2026
Date of board meeting when results were approved 14-05-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 05-05-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Half Yearly
Reporting Quarter Yearly
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Audited
Segment Reporting Single segment
Description of single segment HEALTHCARE
Start date and time of board meeting 14-05-2026   17:45:00
End date and time of board meeting 14-05-2026   18:30:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
(III) Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 31-03-2025
Indicate Company website link for updated RPT policy of the Company https://jtphospitals.com
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
No such matter to disclose for the year under review.


Financial Results — Other than Bank

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-10-2025 01-04-2025
B Date of end of reporting period 31-03-2026 31-03-2026
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
1 Revenue From Operations
Revenue from operations 1,350.76 2,431.80
Other income 51.56 95.53
Total Income 1,402.32 2,527.33
2 Expenses
(a) Cost of materials consumed 111.62 262.58
(b) Purchases of stock-in-trade 0.00 0.00
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade 0.00 0.00
(d) Employee benefit expense 320.49 559.27
(e) Finance costs 80.29 137.50
(f) Depreciation and amortisation expense 46.16 97.29
(g) Other Expenses
1 Other Expenses 815.83 1,373.32
Total other expenses 815.83 1,373.32
Total expenses 1,374.39 2,429.96
3 Profit before exceptional and extraordinary items and tax 27.93 97.37
4 Exceptional items 0.00 0.00
5 Profit before extraordinary items and tax 27.93 97.37
6 Extraordinary items 0.00 0.00
7 Profit before tax 27.93 97.37
8 Tax Expense
Current tax 3.92 22.00
Deferred tax 4.17 4.03
Total tax expenses 8.09 26.03
9 Net Profit Loss for the period from continuing operations 19.84 71.34
10 Profit (loss) from discontinuing operations before tax 0.00 0.00
11 Tax expense of discontinuing operations 0.00 0.00
12 Net profit (loss) from discontinuing operation after tax 0.00 0.00
13 Profit (loss) for period before minority interest 19.84 71.34
14 Share of profit (loss) of associates
15 Profit (loss) of minority interest
16 Net profit (Loss) for the period 19.84 71.34
17 Details of equity share capital
Paid-up equity share capital 1,130.00 1,130.00
Face value of equity share capital 5 5
18 Reserves excluding revaluation reserve 3,953.47
19 Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 0.09 0.32
Diluted earnings (loss) per share from continuing and discontinued operations 0.09 0.32
20 Debt equity ratio 0.4500 0.4500
21 Debt service coverage ratio 2.2300 2.2300
22 Interest service coverage ratio 2.4100 2.4100
23 Disclosure of notes on financial results Textual Information(1)


Text Block

Textual Information(1) 1. The above standalone financial results of the company (“the statement”) have been reviewed by the Audit Committee and subsequently approved by the Board of Directors of the Company at its Meeting held on May 14, 2026 and have been subjected to audit by the statutory auditors of the company on which the auditors have been expressed an unmodified Opinion. 2. The Standalone Financial Results have been prepared in accordance with recognition and measurement principles laid down in the Accounting Standard 25 “Interim Financial Reporting” (As 25) as prescribed under section 133 of the companies act, 2013 (“the Act”) read with the companies (accounting standards) Rules, 2021, as amended from time to time and other accounting principal generally accepted in India. These financial results are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with other relevant rules and circulars issued thereunder. 3. The figures for the Half year ended March 31, 2025 are the balancing figures between audited figures in respect of year ended March 31, 2025 and reviewed year to date figures for the half year ended September 30, 2024. The figures for the Half year ended March 31, 2026 are the balancing figures between audited figures in respect of year ended March 31, 2026 and reviewed year to date figures for the half year ended September 30, 2025. 4. The company is engaged primarily in the business of Operating Multi Speciality Hospitals and all its operations are in India only. Accordingly, there is no separate reportable segment as per AS 17 on “Segment Reporting” in respect of Company. 5. The company’s Equity Shares are listed w.e.f. June 30, 2023 at Emerge Platform of National Stock Exchange of India Ltd. (NSE). 6. As per information and explanation provided by the company the details of utilization of the IPO proceeds upto 31/03/2026 are as below :- [Amount Rs. In Lakhs] Sr. No. Objects as per Prospectus (Offer Document) Amount disclosed in Offer Document Actual Utilized amount as on 31/03/2026 Remarks 1 Repayment / Prepayment in full or part of existing secured debt of the Company. 900.00 900.00 - 2 Funding the working capital requirements of the Company. 600.00 600.00 - 3 Purchase of medical equipments for hospitals of our Company and/or newly acquired or set up hospitals. 913.11 913.11 - 4 Company’s inorganic growth initiatives through acquisitions and other strategic initiatives. 620.00 620.00 - 5 General Corporate Expenses 496.89 496.89 - 6 Issue Expenses 310.00 310.00 - Total Rs. In Lacs 3,840.00 3,840.00 7. Previous year’s/period’s figures have been regrouped/reclassified whenever necessary.


Remarks

20 Debt equity ratio
21 Debt service coverage ratio
22 Interest service coverage ratio


Cash flow statement — indirect

Amount in (Lakhs)

A Date of start of reporting period 01-04-2025
B Date of end of reporting period 31-03-2026
C Whether results are audited or unaudited Audited
D Nature of report standalone or consolidated Standalone
1 Statement of cash flows
Cash flows from used in operating activities
Profit before extraordinary items and tax 97.37
2 Adjustments for reconcile profit (loss)
Adjustments to profit (loss)
Adjustments for finance costs 137.50
Adjustments for depreciation and amortisation expense 97.29
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0.00
Adjustments for unrealised foreign exchange losses gains 0.00
Adjustments for dividend income 0.00
Adjustments for share-based payments 0.00
Other adjustments for which cash effects are investing or financing cash flow 0.00
Other adjustments to reconcile profit (loss) 0.00
Other adjustments for non-cash items (0.43)
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0.00
Total adjustments to profit (loss) 234.36
3 Adjustments for working capital
Adjustments for decrease (increase) in inventories (87.74)
Adjustments for decrease (increase) in trade receivables 3.90
Adjustments for decrease (increase) in other current assets (103.65)
Adjustments for increase (decrease) in trade payables 31.00
Adjustments for increase (decrease) in other current liabilities 524.73
Adjustments for provisions (15.21)
Total adjustments for working capital 353.03
Total adjustments for reconcile profit (loss) 587.39
Net cash flows from (used in) operations 684.76
Dividends received 0.00
Interest paid 0.00
Interest received 0.00
Income taxes paid (refund) (22.00)
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) operating activities before extraordinary items 706.76
Proceeds from extraordinary items 0.00
Payment for extraordinary items 0.00
Net cash flows from (used in) operating activities 706.76
4 Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0.00
Cash flows used in obtaining control of subsidiaries or other businesses 0.00
Other cash receipts from sales of equity or debt instruments of other entities 0.00
Other cash payments to acquire equity or debt instruments of other entities 0.00
Other cash receipts from sales of interests in joint ventures 0.00
Other cash payments to acquire interests in joint ventures 0.00
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0.00
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0.00
Proceeds from sales of property plant and equipment 15.28
Purchase of property plant and equipment 0.00
Proceeds from sales of intangible assets 0.00
Purchase of intangible assets 1,253.75
Cash advances and loans made to other parties 0.00
Cash receipts from repayment of advances and loans made to other parties 0.00
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0.00
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0.00
Dividends received 0.00
Interest received 0.00
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Proceeds from government grants 0.00
Net cash flows from (used in) investing activities before extraordinary items (1,238.47)
Proceeds from extraordinary items 0.00
Payment for extraordinary items 0.00
Net cash flows from (used in) investing activities (1,238.47)
Cash flows from used in financing activities
Proceeds from issuing shares 0.00
Proceeds from issuing other equity instruments 0.00
Proceeds from issuing debentures notes bonds etc 0.00
Proceeds from borrowings 723.63
Repayments of borrowings 101.14
Dividends paid 0.00
Interest paid 137.51
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) financing activities before extraordinary items 484.98
Proceeds from extraordinary items 0.00
Payment for extraordinary items 0.00
Net cash flows from (used in) financing activities 484.98
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes (46.73)
6 Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0.00
Net increase (decrease) in cash and cash equivalents (46.73)
Cash and cash equivalents cash flow statement at beginning of period 1,216.23
Cash and cash equivalents cash flow statement at end of period 1,169.50


Statement of Asset and Liabilities

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2025
Date of end of reporting period 31-03-2026
Whether results are audited or unaudited Audited
Nature of report standalone or consolidated Standalone
Equity and liabilities
1 Shareholders' funds
Share capital 1,130.00
Reserves and surplus 3,953.47
Money received against share warrants 0.00
Total shareholders' funds 5,083.47
2 Share application money pending allotment 0.00
3 Deferred government grants 0.00
4 Minority interest
5 Non-current liabilities
Long-term borrowings 879.71
Deferred tax liabilities (net) 92.54
Foreign currency monetary item translation difference liability account 0.00
Other long-term liabilities
Total of Other long-term liabilities
Long-term provisions 0.00
Total non-current liabilities 972.25
6 Current liabilities
Short-term borrowings 1,223.51
Trade Payables
(A) Total outstanding dues of micro enterprises and small enterprises 0.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 176.58
Total Trade payable 176.58
Other current liabilities
1 Other Current Liabilites 171.18
Total of Other long-term liabilities 171.18
Short-term provisions 37.57
Total current liabilities 1,608.84
Total equity and liabilities 7,664.56
Assets
1 Non-current assets
i Property, Plant and Equipment and Intangible assets
Property, Plant and Equipment 1,257.65
Producing properties 0.00
Intangible assets 1,687.86
Preproducing properties 0.00
Property, Plant and Equipment capital work-in-progress 53.41
Intangible assets under development or work-in-progress 0.00
Total Property, Plant and Equipment and Intangible assets 2,998.92
ii Non-current investments 0.00
v Deferred tax assets (net) 0.00
vi Foreign currency monetary item translation difference asset account 0.00
vii Long-term loans and advances 0.00
Other non-current assets
Total of Other non-current assets
Total non-current assets 2,998.92
Current assets
Current investments 0.00
Inventories 159.01
Trade receivables 2,454.43
Cash and cash equivalents 1,169.50
Bank balance other than cash and cash equivalents 773.30
Short-term loans and advances 109.40
Other current assets
Total of Other current assets
Total current assets 4,665.64
Total assets 7,664.56
Disclosure of notes on assets and liabilities Textual Information(1)


Text Block

Textual Information(1)


Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-10-2025 01-04-2025
Date of end of reporting period 31-03-2026 31-03-2026
Whether results are audited or unaudited Audited Audited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets
Net Segment Asset
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities
Net Segment Liabilities
Disclosure of notes on segments




Details of Impact of Audit Qualification

Amount in (Lakhs)

Whether results are audited or unaudited Audited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 Bela Mehta and Associates Yes 31-01-2027


Signatory Details

Name of signatory
Designation of person
Place
Date


Amount in (Lakhs)

Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)
Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity /subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of the related party transaction ratified by the audit committee Date of Audit Committee Meeting where the ratification was approved Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 AATMAJ HEALTHCARE LIMITED Tushar K Suvagiya Managing Director Loan 621.00 The Transaction has been approved 621.00 14-05-2026 621.00 0.00 621.00 Loan 0 12
2 AATMAJ HEALTHCARE LIMITED Tushar K Suvagiya Managing Director Loan (670.89) The Transaction has been approved (670.89) 14-05-2026 (670.89) 0.00 (670.89) Loan 0 12
3 AATMAJ HEALTHCARE LIMITED APRL Pathlabs Private Limited Entity having interest of Promoter group Any other transaction Expenses 60.01 The Transaction has been approved 60.01 14-05-2026 60.01 0.00 60.01
4 AATMAJ HEALTHCARE LIMITED Dr. Ravi Apte Executive Director Any other transaction Expenses 44.89 The Transaction has been approved 44.89 14-05-2026 44.89 0.00 44.89
5 AATMAJ HEALTHCARE LIMITED Dr. Swati Apte Relative of Director Any other transaction Expenses 0.00 The Transaction has been approved 0.00 14-05-2026 0.00 0.00 0.00
6 AATMAJ HEALTHCARE LIMITED Tushar Suvagiya Managing Director Any other transaction Expenses 67.20 The Transaction has been approved 67.20 14-05-2026 67.20 0.00 67.20
7 AATMAJ HEALTHCARE LIMITED Jignasa Suvagiya Director Any other transaction Expenses 24.00 The Transaction has been approved 24.00 14-05-2026 24.00 0.00 24.00
8 AATMAJ HEALTHCARE LIMITED Karshan Suvagiya Relative of Director Any other transaction Expenses 7.20 The Transaction has been approved 7.20 14-05-2026 7.20 0.00 7.20
9 AATMAJ HEALTHCARE LIMITED Jayaben Suvagiya Relative of Director Any other transaction Expenses 16.80 The Transaction has been approved 16.80 14-05-2026 16.80 0.00 16.80
10 AATMAJ HEALTHCARE LIMITED Dhyey Suvagiya Relative of Director Any other transaction Expenses 16.80 The Transaction has been approved 16.80 14-05-2026 16.80 0.00 16.80
11 AATMAJ HEALTHCARE LIMITED Smital Petroleum Entity having interest of Director Purchase of fixed assets 6.04 The Transaction has been approved 6.04 14-05-2026 6.04 0.00 6.04
Total value of transaction during the reporting period 193.05